Altered bone and mineral metabolism in patients receiving imatinib mesylate Academic Article uri icon

Overview

MeSH Major

  • Bone Remodeling
  • Hypophosphatemia
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines

abstract

  • Hypophosphatemia, with associated changes in bone and mineral metabolism, develops in a proportion of patients taking imatinib for either chronic myelogenous leukemia or gastrointestinal stromal tumors. The drug may inhibit bone remodeling (formation and resorption), even in patients with normal serum phosphate levels.

publication date

  • May 11, 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 16687713

Additional Document Info

start page

  • 2006

end page

  • 13

volume

  • 354

number

  • 19